Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
作者： Kwok-Kin Wong
DOI:
关键词:
摘要: The present invention relates to the treatment of EGFR-mediated disease, particularly cancer, which is resistant tyrosine kinase inhibitor therapies. Methods for cancer and reduction tumor growth in individuals with secondary EGFR mutations, domain standard therapy are provided. provides methods cancers anti-EGFR antibodies. recurrent lung including non-small cell carcinoma inhibitors, antibody mAb806 described.
glgoo.top参考文章(1,248)
Serge Bénichou, Geneviève lnchauspé, Random Fragment Libraries Using Yeast Expression Plasmid Methods of Molecular Biology. ,vol. 66, pp. 241- 255 ,(1996) , 10.1385/0-89603-375-9:241
John Mendelsohn, Targeting the epidermal growth factor receptor for cancer therapy. Journal of Clinical Oncology. ,vol. 20, ,(2002)
William E. Karnes, John H. Walsh, S. Vincent Wu, Richard S. Kim, Martin G. Martin, Helen C. Wong, John Mendelsohn, Jae-Gahb Park, Frank Cuttitta, Autonomous proliferation of colon cancer cells that coexpress transforming growth factor α and its receptor: Variable effects of receptor-blocking antibody Gastroenterology. ,vol. 102, pp. 474- 485 ,(1992) , 10.1016/0016-5085(92)90093-E
M. L. Levitt, J. E. Mayotte, Wendong Lei, Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Research. ,vol. 19, pp. 221- 228 ,(1999)
Tsugu A, Kijima H, Ohnishi Y, Abe Y, Takamiya Y, Sato O, Ueyama Y, Nakamura M, Tamaoki N, Yamazaki H, Localization of aberrant messenger RNA of epidermal growth factor receptor (EGFR) in malignant glioma. Anticancer Research. ,vol. 17, pp. 2225- 2232 ,(1997)
Vass Wc, Lowy Dr, Helin K, Allevato G, Beguinot L, Velu T, Martin P, The biological activity of the human epidermal growth factor receptor is positively regulated by its C-terminal tyrosines. Oncogene. ,vol. 6, pp. 825- ,(1991)
Francisco J. Esteva, Monica Fornier, Andrew D. Seidman, Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Seminars in Oncology. ,vol. 27, pp. 38- 45 ,(2000)
J. Crawford, A. B. Sandler, L. A. Hammond, J. Schiller, C. Belani, M. Kozloff, D. Johnson, A. Fleishman, S. Lee, K. Takeshita, ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. ,vol. 22, pp. 7083- 7083 ,(2004) , 10.1200/JCO.2004.22.90140.7083
Christopher S. Conner, Therapy with monoclonal antibodies. Annals of Pharmacotherapy. ,vol. 18, pp. 65- 66 ,(1984) , 10.1177/106002808401800111
A M Karameris, V G Gorgoulis, I Poulias, C Barbatis, Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients. Modern Pathology. ,vol. 8, pp. 758- 764 ,(1995)